JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

LGI3 promueve la progresión del carcinoma de células renales reorganizado por TFE3 a través del eje GEMIN6/AURKB

  • 0Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Oncogene +

|

23 de agosto de 2025

|

23 de agosto de 2025

Ver abstracta en PubMed

Resumen

Este resumen es generado por máquina.

El miembro 3 de la familia LGI rico en leucina (LGI3) impulsa el carcinoma de células renales reorganizado por TFE3 (TFE3-RCC) mediante la estabilización de GEMIN6, que promueve la aurora B quinasa. Dirigirse a LGI3, GEMIN6 o AURKB puede ofrecer nuevas terapias para el TFE3-RCC.

Área De La Ciencia

  • En el campo de la oncología
  • Biología molecular
  • La genética

Sus Antecedentes

  • El carcinoma de células renales reorganizado por TFE3 (TFE3-RCC) es agresivo y tiene un mal pronóstico.
  • Los factores moleculares de la tumorigénesis del TFE3-RCC no se comprenden completamente.

Objetivo Del Estudio

  • Identificar objetivos posteriores de la proteína de fusión TFE3 en el TFE3-RCC.
  • Para aclarar el mecanismo de LGI3 en la progresión de TFE3-RCC.
  • Evaluar las estrategias terapéuticas dirigidas a la vía LGI3.

Principales Métodos

  • Los ensayos del reporter de luciferasa confirman la unión de TFE3 al promotor LGI3.
  • Proliferación celular, migración y análisis de invasión.
  • Ensayos de borrado y ubiquitinación occidentales para estudiar las interacciones de proteínas.
  • Ensayos de sensibilidad a fármacos de organoides y líneas celulares.

Principales Resultados

  • LGI3 es un objetivo transcripcional directo de la proteína de fusión TFE3.
  • LGI3 promueve la proliferación, migración e invasión de las células TFE3-RCC.
  • LGI3 estabiliza GEMIN6 inhibiendo su ubiquitinación, lo que lleva a un aumento de la maduración del ARNm de la aurora B quinasa (AURKB).
  • LGI3, GEMIN6 y AURKB están regulados al alza en los tejidos humanos de TFE3-RCC.
  • Los fármacos dirigidos a GEMIN6 o AURKB inhibieron el crecimiento de TFE3-RCC in vitro y en organoides.

Conclusiones

  • LGI3 es un factor oncogénico clave en TFE3-RCC, actuando a través del eje LGI3-GEMIN6-AURKB.
  • Esta vía representa una nueva vulnerabilidad terapéutica en el TFE3-RCC.
  • La orientación hacia GEMIN6 o AURKB es prometedora para el tratamiento de TFE3-RCC.

Videos de Conceptos Relacionados

The Retinoblastoma Gene 01:20

4.2K

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

mTOR Signaling and Cancer Progression 03:03

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle 02:38

6.6K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

TGF - β Signaling Pathway 01:16

7.6K

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

Tumor Progression 02:07

6.5K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal 01:22

2.3K

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.